AstraZeneca Provides Update On RECENTIN⢠Clinical Development Programme
- Details
- Category: AstraZeneca
AstraZeneca today announced that its HORIZON III Phase II/III head-to-head study of RECENTIN™ (cediranib, AZD2171) with chemotherapy versus bevacizumab (Avastin™) with chemotherapy in patients with first line metastatic colorectal cancer (CRC) will be progressing directly into Phase III at 20mg.
Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik
- Details
- Category: Pfizer
Pfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion.
Novartis Vaccines Institute for Global Health (NVGH) is the first institute with nonprofit mission
- Details
- Category: Novartis
Novartis announced the opening of a new research institute in Siena with a nonprofit mission to exclusively focus on the development of vaccines for diseases of the developing world. The Novartis Vaccines Institute for Global Health (NVGH) is the first institute of its kind to be set up by a major vaccine manufacturer.
Nycomed creates a leading specialty pharmaceutical player in dermatology
- Details
- Category: Nycomed
Nycomed successfully completed the acquisition of BradleyPharmaceuticals, a company focused on niche therapeutic markets in the United States. Bradley will be integrated into the US specialty business Nycomed US. The acquisition makes Nycomed US a leader in the US dermatology market, with combined annualised dermatology sales of $450 million.
AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
- Details
- Category: AstraZeneca
AstraZeneca today announced it intends to seek reconsideration or reversal of a verdict in the Montgomery County Circuit Court awarding $40 million in compensatory damages and $175 million in punitive damages for alleged false and misleading reporting of prices for drugs reimbursed by the Alabama State Medicaid Agency in the US.
Shire plc accelerating new product sales drive revenue growth of 36%
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 â a year which has seen significant growth in launched products.
Financial Highlights, 2007 Full Year:
Financial Highlights, 2007 Full Year:
New price reductions for GSK antiretrovirals in the world's poorest countries
- Details
- Category: GlaxoSmithKline
GSK today announced significant new price reductions for its HIV medicines offered on a not-for-profit basis to the world's poorest countries. This reduction is the fifth time the company has made a price reduction as part of its pioneering preferential pricing policy originally introduced in 1997.
More Pharma News ...
- Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
- Bayer and Onyx Provide Update on Phase III Trial of Nexavar®
- Trasylol® - One Thousand Lives A Month
- EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline
- FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992
- Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin)
- Pharmion and MethylGene Announce U.S. Orphan Drug Designation